Dr Mark Wildgust: Daratumumab Critical to Improving Patient Response

January 25th 2021, 8:00pm


Daratumumab represents an important addition to the armamentarium of care for improving patient outcomes, said Mark Wildgust, PhD, vice president of Global Medical Affairs/Oncology at Janssen.

Higher Mortality Seen Among HSCT Recipients Who Contract COVID-19

January 20th 2021, 9:10pm


Recipients of hematopoietic stem-cell transplantation (HSCT) who develop coronavirus disease 2019 (COVID-19) may be predisposed to a greater mortality rate if they meet certain disease criteria.

Emerging Treatment Options in Relapsed Refractory Multiple Myeloma

January 20th 2021, 7:15pm


A panel of experts discuss existing treatment options for relapsed/refractory multiple myeloma and provide practical considerations for regimen selection and emerging treatment options.

ASH 2020: COVID-19 and Hematology

January 20th 2021, 7:00pm


Anthony Fauci gave his insight on the coronavirus disease 2019 (COVID-19) for immunocompromised populations at ASH 2020, and leading organizations released fact sheets and recommendations.

High-Antibody Convalescent Plasma Associated With Lower Mortality Among Patients With COVID-19

January 14th 2021, 9:00pm


A comparison of 3 levels of SARS-CoV-2 antibodies in convalescent plasma shows that the 30-day death rate was lowest in the group receiving high-titer plasma.

Natural Killer Cells Could Play Key Role in Fight Against MM

January 12th 2021, 6:16pm


Emerging research into natural killer cells has shown promise, but the findings are complicated by the heterogeneity of multiple myeloma (MM).

Risk Factors for Increased Mortality Among Patients With MM, COVID-19 Identified

January 7th 2021, 2:00pm


Age, renal disease, and suboptimal myeloma control were among the many factors identified in a recent study as increasing the risk of death from coronavirus disease 2019 (COVID-19) for patients being treated for multiple myeloma (MM).

Dr Robert Massie: Untreated Pooled Plasma Enabled Unchecked Virus Transmission

January 5th 2021, 8:45pm


Decades ago, companies refused to heat-treat their blood products, which resulted in pooled plasma, among others, enabling many viruses to be transmitted, noted Robert K. Massie Jr, PhD, MA, of the Society for Progress.

Metabolic Biomarkers Could Predict Prognosis, Treatment Outcomes in MM

December 30th 2020, 5:00am


New research shows metabolic biomarkers could be meaningful tools for predicting treatment outcomes in patients, based on a comparison of biomarkers, clinical characteristics, and therapeutic efficacy.

Top 5 Most-Read Hematology Articles for 2020

December 28th 2020, 1:15pm


Gene-editing therapy in sickle cell disease and advances in multiple myeloma dominated hematology news in 2020.